Neurological disorders Archives

multiple sclerosis zinbryta daclizumab biogen abbvie

News and Trends 6 Jul 2016

Newly Approved therapy reduces frequency of Multiple Sclerosis relapses by 54%

Biogen and AbbVie have been granted EU marketing authorization for Zinbryta (daclizumab), to treat adult patients with relapsing forms of multiple sclerosis. Relapse frequency per year was shown to be reduced by up to 45% against other treatments, and 54% against placebo. Biogen is trying to emphasise the need for choice of treatments for MS, as the […]

July 6, 2016 - 3 minutesmins - By Dani Bancroft

affiris peptide vaccine affitope cholesterol

News and Trends 29 Jun 2016

Vienna-based Biotech raises €10M to fight Metabolic diseases and Parkinson’s

AFFiRiS has received €10M from previous investors and one additional backer, adding up to €130M in total funding (half from grants and licensing incomes). This money fuels a pipeline in cardiometabolic and neurodegenerative diseases as more candidates break into clinical development. Based at the Campus Vienna Biocenter (Austria), AFFiRiS is developing immunotherapies to prevent chronic diseases. […]

June 29, 2016 - 2 minutesmins - By Denise Neves Gameiro

News and Trends 23 Jun 2016

Alzheimer’s closer to a Vaccine with new Slovakian Phase II Trial

Axon Neuroscience is starting a Phase II trial with its immunotherapy for Alzheimer’s disease, which redirects the immune system against defective Tau proteins, thought to be the main cause of this major disease. Alzheimer’s disease is the cause of up to 70% of dementia cases, according to WHO, which translates in over 30 million patients […]

June 23, 2016 - 2 minutesmins - By Denise Neves Gameiro

kings college depression biomarker diagnostic

News and Trends 14 Jun 2016

New Biomarkers could make Personalized Medicine for Depression

Researchers from King’s College London have succeeded in developing a blood test that can help choose the best treatment for depression patients – a big improvement over the current trial-and-error approach. Depression doesn’t seem to be a particularly popular indication for biotechs, unlike other nervous systems diseases that reached significant milestones in the last year. Moreover, one […]

June 14, 2016 - 3 minutesmins - By Denise Neves Gameiro

huntingtons rochester copenhagen glia transplant

News and Trends 9 Jun 2016

Brain Cell Transplant could help with incurable Neurodegenerative Disease

Researchers from Copenhagen and the US have succeeded in slowing the progression of Huntington’s disease in mice with a transplant of healthy human brain cells. This provides a new route to tackle this incurable fatal disease. Cell therapies are promising for some of the most serious diseases, from their role in cancer treatment (one of the […]

June 9, 2016 - 3 minutesmins - By Denise Neves Gameiro

News and Trends 17 May 2016

New Italian Drug is FDA approved for trials in Rare Neurological Disease

Newron sees its Investigational New Drug application approved by the FDA. It can now begin clinical trials for Rett Syndrome patients – a rare neurological disorder. Based near Milan (Italy), Newron is a Biopharma developing therapies for diseases of the central nervous system (CNS). Last year it raised over €23M to advance its pipeline, which features candidates […]

May 17, 2016 - 2 minutesmins - By Denise Neves Gameiro

interview biotrinity labiotech dementia fund

News and Trends 28 Apr 2016

Interviewing the CSO of the newly €90M fund willing to finally tackle Dementia

I had the chance to talk with Tetsuyuki Maruyama, the CSO of the relatively new Dementia Discovery Fund – our final interview for #BioTrinity2016 in London. The high risk nature of doing trials for Dementia patients means in the past the market for this area of Neurodegenerative disease has been tough. However, the need for […]

April 28, 2016 - 1 minutemin - By Philip Hemme

pharnext pleodrug charcot marie tooth cmt1a

News and Trends 27 Apr 2016

French Pleodrug for Rare Neurological Disease opens up phase III trial in US

Pharnext is opening their first US study sites for a phase III trial in a rare neuropathy – a milestone in the development of Pharnext’s leading candidate. Based in Paris (France), Pharnext is developing new therapies for neurological conditions, including rare diseases such as Charcot-Marie-Tooth Disease. Pharnext uses network pharmacology to discover synergistic combinations of drugs […]

April 27, 2016 - 2 minutesmins - By Denise Neves Gameiro

Katharine dowson bioart science gallery hiv brain malformation glass

News and Trends 23 Apr 2016

BioArt : Katharine Dowson’s Brain Boxes, Crystal Chromosomes & HIV Vaccine Work

Represented by the GV Art Gallery in London, Katharine Dowson is a glass sculptor who is well established in the BioArt community as an Anatomical and medicine specialist. Katharine studied at the Royal College of Art and Camberwell in London, with a focus spanning to include the anatomical form (particularly the Nervous system) to infectious diseases and developmental research into a […]

April 23, 2016 - 4 minutesmins - By Dani Bancroft

cannabis cannabidiol gw pharmaceuticals tuberous sclerosis complex epilepsy biotech fda orphan drug trials

News and Trends 22 Apr 2016

UK Cannabis Biotech gets another Orphan Drug Designation by the FDA

Cambridge based GW Pharmaceuticals has now been granted Orphan Drug Designation from FDA for Cannabidiol drug to treat a 3rd rare genetic form of epilepsy. GW Pharmaceuticals has been granted Orphan Drug Designation for cannabidiol (CBD) for the treatment of Tuberous Sclerosis Complex (TSC). Epidiolex is a liquid formulation of pure plant-derived CBD, which is in development for […]

April 22, 2016 - 2 minutesmins - By Dani Bancroft

Gensight gene therapy biotech bernard gilly labiotech

News and Trends 18 Apr 2016

ITW: This Biotech Startup wants to fix Youth Blindness with a Gene Therapy

While on a stop in New York, I had a chance to chat with Bernard Gilly, the founder and CEO of the Paris biotech GenSight. I wanted to learn more about the company, which is one of the only examples in the World using Gene therapy to treat specific and rare types of blindness. GenSight […]

April 18, 2016 - 6 minutesmins - By Philip Hemme

geneuro euronext multiple sclerosis biotech

News and Trends 16 Apr 2016

First Euronext Biotech IPO of 2016 is Swiss, and for Multiple Sclerosis!

We last wrote about GeNeuro in January, when they announced the launch of an IPO for their Multiple Sclerosis phase IIb trial. Now, as of yesterday they are listed on the Euronext Paris market. GeNeuro (in Geneva) is developing therapies and diagnostic tools for diseases associated with the expression of the human endogenous retrovirus MSRV, such […]

April 16, 2016 - 2 minutesmins - By Dani Bancroft

Resources

Categories

T cell engagers: A promising, fast-growing field for cancer and autoimmune disease treatments

The biggest biotech funding rounds in February 2025

Approaches

Therapeutic areas

Grab your free report on 3D organoids and explore their future potential

World Cancer Day: trends in cancer therapeutics to look forward to in 2025

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

T cell engagers: A promising, fast-growing field for cancer and autoimmune disease treatments

The biggest biotech funding rounds in February 2025

Grab your free report on 3D organoids and explore their future potential

World Cancer Day: trends in cancer therapeutics to look forward to in 2025

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Neurological disorders

Newly Approved therapy reduces frequency of Multiple Sclerosis relapses by 54%

Vienna-based Biotech raises €10M to fight Metabolic diseases and Parkinson’s

Alzheimer’s closer to a Vaccine with new Slovakian Phase II Trial

New Biomarkers could make Personalized Medicine for Depression

Brain Cell Transplant could help with incurable Neurodegenerative Disease

New Italian Drug is FDA approved for trials in Rare Neurological Disease

Interviewing the CSO of the newly €90M fund willing to finally tackle Dementia

French Pleodrug for Rare Neurological Disease opens up phase III trial in US

BioArt : Katharine Dowson’s Brain Boxes, Crystal Chromosomes & HIV Vaccine Work

UK Cannabis Biotech gets another Orphan Drug Designation by the FDA

ITW: This Biotech Startup wants to fix Youth Blindness with a Gene Therapy

First Euronext Biotech IPO of 2016 is Swiss, and for Multiple Sclerosis!

Subscribe to our newsletter to get the latest biotech news!

T cell engagers: A promising, fast-growing field for cancer and autoimmune disease treatments

The biggest biotech funding rounds in February 2025

Grab your free report on 3D organoids and explore their future potential

World Cancer Day: trends in cancer therapeutics to look forward to in 2025

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

T cell engagers: A promising, fast-growing field for cancer and autoimmune disease treatments

The biggest biotech funding rounds in February 2025

Grab your free report on 3D organoids and explore their future potential

World Cancer Day: trends in cancer therapeutics to look forward to in 2025

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!